(WFRF:(Busse R. S.)) srt2:(2010-2014)
Search: (WFRF:(Busse R. S.)) srt2:(2010-2014) > 24-h duration of th...
- 5 of 7
- Previous record
- Next record
- To hitlist
24-h duration of the novel LABA vilanterol trifenatate in asthma patients treated with inhaled corticosteroids
-
- Lötvall, Jan, 1956 (author)
- Gothenburg University,Göteborgs universitet,Krefting Research Centre
- Bateman, E. D. (author)
- Bleecker, E. R. (author)
- show more...
- Busse, W. W. (author)
- Woodcock, A. (author)
- Follows, R. (author)
- Lim, J. (author)
- Stone, S. (author)
- Jacques, L. (author)
- Haumann, B. (author)
- show less...
- (creator_code:org_t)
- 2012-02-23
- 2012
- English.
- In: European Respiratory Journal. - : European Respiratory Society (ERS). - 0903-1936 .- 1399-3003. ; 40:3, s. 570-579
- Journal article (peer-reviewed)
Abstract
Subject headings
Close
- Current guidelines recommend adding a long-acting inhaled beta(2)-agonist (LABA) to inhaled corticosteroids (ICS) in patients with uncontrolled asthma. This study evaluated the novel, once-daily LABA vilanterol trifenatate (VI) in asthma patients who remained symptomatic despite existing ICS therapy. The study involved a randomised, double-blind, placebo-controlled trial of VI (3, 6.25, 12.5, 25 and 50 mu g), administered once daily in the evening by dry powder inhaler for 28 days, in asthma patients aged >= 12 yrs symptomatic on current ICS therapy. The primary end-point was trough (24 h post-dose) forced expiratory volume in 1 s (FEV1); secondary end-points were weighted mean FEV1, peak expiratory flow (PEF), symptom-/rescue-free 24-h periods, and safety. A significant relationship was observed between VI dose and improvements in trough FEV1 (p=0.037). Statistically significant increases in mean trough FEV1, relative to placebo, were documented for VI 12.5-50 mu g (121-162 mL; p <= 0.016). Dose-related effects of VI were observed on weighted mean (0-24 h) FEV1, morning/evening PEF, and symptom-/rescue-free 24-h periods. All doses of VI were well tolerated with low incidences of recognised LABA-related adverse events (tremor 0-2%; palpitations 0-2%; glucose effects 0-1%; potassium effects 0-<1%). Once-daily VI 12.5-50 mu g resulted in prolonged bronchodilation of at least 24 h with good tolerability in asthma patients receiving ICS. Based on the overall efficacy and adverse event profile from this study, the optimum dose of VI appears to be 25 mg.
Subject headings
- MEDICIN OCH HÄLSOVETENSKAP -- Klinisk medicin (hsv//swe)
- MEDICAL AND HEALTH SCIENCES -- Clinical Medicine (hsv//eng)
Keyword
- Add-on therapy
- asthma management
- bronchodilator
- quality-of-life
- fluticasone furoate
- controlled-trial
- salmeterol
- formoterol
- efficacy
- therapy
- sample
Publication and Content Type
- ref (subject category)
- art (subject category)
Find in a library
- European Respiratory Journal (Search for host publication in LIBRIS)
To the university's database
- 5 of 7
- Previous record
- Next record
- To hitlist
Find more in SwePub
- By the author/editor
- Lötvall, Jan, 19 ...
- Bateman, E. D.
- Bleecker, E. R.
- Busse, W. W.
- Woodcock, A.
- Follows, R.
- show more...
- Lim, J.
- Stone, S.
- Jacques, L.
- Haumann, B.
- show less...
- About the subject
-
- MEDICAL AND HEALTH SCIENCES
- MEDICAL AND HEAL ...
- and Clinical Medicin ...
- Articles in the publication
- European Respira ...
- By the university
- University of Gothenburg
Search outside SwePub
- Extend your search to:
- Google Book Search
- Google Scholar
Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.
- Copyright © LIBRIS - National Library Systems
- LIBRIS.kb.se
